How PMs aim for impact through investment in cancer treatment citywireselector.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from citywireselector.com Daily Mail and Mail on Sunday newspapers.
This Puts You Most at Risk for COVID, Says Dr. Fauci
By Leah Groth of ETNT Health |
This Puts You Most at Risk for COVID, Says Dr. Fauci
Early on in the pandemic, it was established that certain people are more at risk of severe COVID-19 infection and even death. Dr. Anthony Fauci, the nation s leading infectious disease expert, gave the keynote remarks at the American Association for Cancer Research highlighting the importance of understanding who, exactly, falls into the high-risk category. Click through to see if you have any of the conditions on his list, and to ensure your health and the health of others, don t miss these Sure Signs You ve Already Had Coronavirus.
Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Abstract Accepted for Presentation at AACR 2021 Annual Meeting
/
February 3, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that data from non-human primate studies of the company s proprietary fully human Interleukin 12 (IL-12) therapeutic candidate, SON-1010, will be presented at the upcoming American Association for Cancer Research (AACR) Virtual Annual Meeting 2021, April 10-15 and May 17-21.
Details of the abstract and poster presentation are as follows:
Title: Toxicity profile of interleukin 12 attached to a fully human albumin binding domain (FHABTM) in Cynomolgus macaques
Abstract Number: 1589
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation at AACR 2021 Annual Meeting theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
Date Time
Examining resistance to breast cancer treatments
The combination of CDK4/6 inhibitors with endocrine therapy is the standard of care for patients with estrogen receptor-positive (ER+) and HER2-negative (ER+/HER2-) metastatic breast cancer. However, a subset of patients will have tumors with intrinsic resistance to this therapy and most patients will develop resistant disease at some point during treatment.
Researchers at the Lester and Sue Smith Breast Center and the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine examined gene expression data from preclinical models of ER+ breast cancer and from patients with early ER+/HER2- breast cancer who were participating in neoadjuvant trials of CDK4/6 inhibitors and found an association between high interferon (IFN) signaling and resistance to the treatment. The findings published in Clinical Cancer Research, a journal of the American Association for Cancer Research, may aid in helping doctors identify whi